Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 332 followers
Latest posts
Last updated 39 minutes ago
ICH E22 General considerations for patient preference studies - Scientific guideline
about 1 hour ago
ICH E22 General considerations for patient preference studies - Scientific guideline
Appendix 1: Acceptable intakes established for N-nitrosamines
about 1 hour ago
Appendix 1: Acceptable intakes established for N-nitrosamines
Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised
about 21 hours ago
Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Hemangiol, propranolol, Date of authorisation: 23/04/2014, Revision: 8, Status: Authorised
about 20 hours ago
Human medicines European public assessment report (EPAR): Hemangiol, propranolol, Date of authorisation...
Human medicines European public assessment report (EPAR): Balversa, erdafitinib, Date of authorisation: 22/08/2024, Revision: 4, Status: Authorised
about 21 hours ago
Human medicines European public assessment report (EPAR): Balversa, erdafitinib, Date of authorisation...
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 75, Status: Authorised
about 21 hours ago
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
about 21 hours ago
Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Date of authorisation...
Human medicines European public assessment report (EPAR): Qalsody, tofersen, Date of authorisation: 29/05/2024, Revision: 3, Status: Authorised
about 21 hours ago
Human medicines European public assessment report (EPAR): Qalsody, tofersen, Date of authorisation...
Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 24, Status: Authorised
about 21 hours ago
Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation...